C4 THERAPEUTICS INC (CCCC:NASDAQ)
$3.81 -0.11 (-2.8061%)
Analysed C4 THERAPEUTICS INC (CCCC:NASDAQ) News Sources
C4 Therapeutics to Participate in Upcoming Conferences
20-05-2026
yahoo.com
Emerging Hope in Multiple Myeloma Market: 7 Late-Stage Therapies Nearing the Finish Line | DelveInsight
25-05-2026
yahoo.com
Has ABCELLERA BIOLG (ABCL) Outpaced Other Medical Stocks This Year?
01-06-2026
yahoo.com
C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?
01-06-2026
yahoo.com
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
11-06-2026
yahoo.com
C4 Therapeutics Reports 53% Response Rate for Cemsidomide at RP2D
11-06-2026
yahoo.com
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
18-06-2026
yahoo.com
C4 Therapeutics (CCCC) Gains Over the Past Month, Can It Go Higher?
03-07-2026
yahoo.com
C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know
03-07-2026
yahoo.com
Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?
07-07-2026
yahoo.com
What is the current price of C4 THERAPEUTICS INC (CCCC:NASDAQ)?
The current price of C4 THERAPEUTICS INC (CCCC:NASDAQ) is $3.81.
C4 THERAPEUTICS INC (CCCC:NASDAQ) absolute price change since previous trading day?
The absolute price change of C4 THERAPEUTICS INC (CCCC:NASDAQ) since the previous trading day is $-0.11.
C4 THERAPEUTICS INC (CCCC:NASDAQ) percentage price change since previous trading day?
The percentage price change of C4 THERAPEUTICS INC (CCCC:NASDAQ) since the previous trading day is -2.8061%.
What is the most recent average sentiment score for C4 THERAPEUTICS INC (CCCC:NASDAQ)?
The most recent average sentiment score for C4 THERAPEUTICS INC (CCCC:NASDAQ) is 81 out of 100.
What is the most recent average sentiment for C4 THERAPEUTICS INC (CCCC:NASDAQ)?
The most recent sentiment for C4 THERAPEUTICS INC (CCCC:NASDAQ) is .
SEC-8K** Filing Available For C4 THERAPEUTICS INC (CCCC:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.